A Phase II, Randomized, Double-Blind, Placebo-Controlled Twice-Daily Dosing Study of NBI-56418 in Endometriosis

Study Identifier
NBI-56418-0504
CT.gov Identifier
NBI-56418-0504
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Endometriosis
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female
    Age
    N/A
    Inclusion and Exclusion Criteria

    Protocol Summary

    To assess the effects of NBI-56418 for 12 weeks in subjects with endometriosis

    Study Locations

    No locations found.